远程医疗无检测药物流产的有效性、安全性与可接受性:全国队列研究
该全国队列研究比较了传统面对面超声评估模式与远程医疗混合模式(含无检测远程医疗)下药物流产的结果。研究发现远程医疗混合模式缩短等待时间,更多流产在≤6周妊娠时进行,治疗成功率、严重不良事件和异位妊娠发生率无差异,且可接受性高。
要点
- 远程医疗混合模式缩短转诊至治疗等待时间4.2天,更多流产在≤6周妊娠时进行。
- 治疗成功率、严重不良事件和异位妊娠发生率在两种模式间无差异。
- 远程医疗可接受性高,96%满意,80%未来偏好远程医疗。
核心结论
- 远程医疗混合模式(含无检测远程医疗和无需超声的治疗)有效、安全、可接受,并改善就医可及性。
研究设计与样本
- 全国队列分析,比较2020年1-3月传统模式(面对面超声,n=22 158)与2020年4-6月远程医疗混合模式(n=29 984,其中18 435例为无检测远程医疗)的药物流产结局。
- 样本共52 142例,占全国所有药物流产的85%。
主要发现
- 远程医疗混合模式平均等待时间缩短4.2天,≤6周妊娠流产比例更高(40% vs 25%,P<0.001)。
- 治疗成功率(98.8% vs 98.2%,P>0.999)、严重不良事件(0.02% vs 0.04%,P=0.557)和异位妊娠发生率(0.2% vs 0.2%,P=0.796)无差异。
- 远程医疗混合模式中估计0.04%在流产时超过10周妊娠,均在家中安全完成。
- 远程医疗混合模式内,远程医疗的有效性高于面对面护理(99.2% vs 98.1%,P<0.001)。
- 远程医疗可接受性高(96%满意),80%报告未来偏好远程医疗。
临床怎么用
- 对于≤69天妊娠的药物流产,可考虑采用包含无检测远程医疗和无需超声评估的远程医疗混合模式。
- 该模式可缩短等待时间,使更多流产在早期妊娠进行,且不增加严重不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare outcomes before and after implementation of medical abortion (termination of pregnancy) without ultrasound via telemedicine. DESIGN: Cohort analysis. SETTING: The three main abortion providers. POPULATION OR SAMPLE: Medical abortions at home at ≤69 days' gestation in two cohorts: traditional model (in-person with ultrasound, n = 22 158) from January to March 2020 versus telemedicine-hybrid model (either in person or via telemedicine without ultrasound, n = 29 984, of whom 18 435 had no-test telemedicine) between April and June 2020. Sample (n = 52 142) comprises 85% of all medical abortions provided nationally. METHODS: Data from electronic records and incident databases were used to compare outcomes between cohorts, adjusted for baseline differences. MAIN OUTCOME MEASURES: Treatment success, serious adverse events, waiting times, gestation at treatment, acceptability. RESULTS: Mean waiting time from referral to treatment was 4.2 days shorter in the telemedicine-hybrid model and more abortions were provided at ≤6 weeks' gestation (40% versus 25%, P < 0.001). Treatment success (98.8% versus 98.2%, P > 0.999), serious adverse events (0.02% versus 0.04%, P = 0.557) and incidence of ectopic pregnancy (0.2% versus 0.2%, P = 0.796) were not different between models. In the telemedicine-hybrid model, 0.04% were estimated to be over 10 weeks' gestation at the time of the abortion; all were completed safely at home. Within the telemedicine-hybrid model, effectiveness was higher with telemedicine than in-person care (99.2% versus 98.1%, P < 0.001). Acceptability of telemedicine was high (96% satisfied) and 80% reported a future preference for telemedicine. CONCLUSIONS: A telemedicine-hybrid model for medical abortion that includes no-test telemedicine and treatment without an ultrasound is effective, safe, acceptable and improves access to care. TWEETABLE ABSTRACT: Compelling evidence from 52 142 women shows no-test telemedicine abortion is safe, effective and improves care.
引用
- Aiken A, Lohr PA, Lord J, et al. Effectiveness, safety and acceptability of no-test medical abortion (termination of pregnancy) provided via telemedicine: a national cohort study. BJOG. 2021. PMID: 33605016. doi:10.1111/1471-0528.16668
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。